Rajesh V Lalla1, Mark M Schubert, Rene-Jean Bensadoun, Dorothy Keefe. 1. Department of Oral Health and Diagnostic Sciences MC1605, University of Connecticut Health Center, 263, Farmington Avenue, Farmington, 06030-1605, USA. lalla@nso2.uchc.edu
Abstract
BACKGROUND: Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications. MATERIALS AND METHODS: In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis. RESULTS: This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention. CONCLUSION: Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.
BACKGROUND:Alimentary mucositis is a significant complication of cancer therapy, with important clinical and economic implications. MATERIALS AND METHODS: In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology conducted an evidence-based review of the literature on alimentary mucositis. The goal of this literature review was to update previously published guidelines for the management of mucositis. RESULTS: This article reports the findings of the subgroup charged with reviewing the literature related to anti-inflammatory interventions. Considerable preclinical and clinical evidence suggests that the use of anti-inflammatory agents may be a promising approach to reduce the severity of mucositis. However, there was not enough evidence to support any new guidelines advocating the use of any specific anti-inflammatory intervention. CONCLUSION: Thus, there is a need for well-designed clinical trials evaluating the use of anti-inflammatory agents in the management of mucositis.
Authors: Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis Journal: Cancer Date: 2004-05-01 Impact factor: 6.860
Authors: Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein Journal: Cancer Date: 2003-10-01 Impact factor: 6.860
Authors: N Nicolopoulos; A Mantidis; E Stathopoulos; S Papaodysseas; J Kouvaris; H Varveris; C Papavasiliou Journal: Radiother Oncol Date: 1985-01 Impact factor: 6.280
Authors: A Dueñas-Gonzalez; P Sobrevilla-Calvo; M Frias-Mendivil; D Gallardo-Rincon; F Lara-Medina; L Aguilar-Ponce; E Miranda-Lopez; J Zinser-Sierra; E Reynoso-Gomez Journal: Bone Marrow Transplant Date: 1996-05 Impact factor: 5.483
Authors: Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson Journal: Support Care Cancer Date: 2011-10-01 Impact factor: 3.603
Authors: Ourania Nicolatou-Galitis; Triantafyllia Sarri; Joanne Bowen; Mario Di Palma; Vassilios E Kouloulias; Pasquale Niscola; Dorothea Riesenbeck; Monique Stokman; Wim Tissing; Eric Yeoh; Sharon Elad; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-05-24 Impact factor: 3.603
Authors: Ornella Letari; Catherine Booth; Albino Bonazzi; Paolo Garofalo; Francesco Makovec; Lucio C Rovati; Gianfranco Caselli Journal: Cancer Chemother Pharmacol Date: 2009-12-30 Impact factor: 3.333